Drug intelligence / Profile preview

docetaxel + 5-fluorouracil + hydroxyurea + capecitabine

Development stage: Preclinical
Lead developer: Sanofi
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination chemotherapy regimen consisting of docetaxel, 5-fluorouracil, hydroxyurea, and capecitabine. This combination likely leverages the synergistic effects of these agents in treating cancer. Docetaxel is a taxoid antineoplastic agent, 5-fluorouracil is a fluoropyrimidine antimetabolite, hydroxyurea is an antineoplastic agent, and capecitabine is an oral fluoropyrimidine prodrug that converts to 5-fluorouracil in the body.

Other names: docetaxel + 5-fluorouracil + hydroxyurea + capecitabineDFHX-CapTPF-CapHX variant

Targets

RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)

Beyond the preview

Go deeper on docetaxel + 5-fluorouracil + hydroxyurea + capecitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + 5-fluorouracil + hydroxyurea + capecitabine.

Explore the full profile